Chemo-free BRCA-targeted Neoadjuvant Strategy

NCT05209529 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Withdrawn interest from grant provider

Conditions

TNBC - Triple-Negative Breast Cancer
BRCA1 Mutation
BRCA2 Mutation

Interventions

DRUG: olaparib
DRUG: Durvalumab

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]